Globe Newswire (Tue, 13-Jan 4:30 PM ET)
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Dexcom (DXCM)
TipRanks (Tue, 13-Jan 11:40 AM ET)
TipRanks (Mon, 12-Jan 9:46 PM ET)
TipRanks (Mon, 12-Jan 9:26 PM ET)
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
Globe Newswire (Mon, 12-Jan 8:00 AM ET)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 9-Jan 4:01 PM ET)
Globe Newswire (Thu, 8-Jan 4:45 PM ET)
Market Chameleon (Wed, 7-Jan 4:24 AM ET)
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
Globe Newswire (Tue, 6-Jan 11:15 PM ET)
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Globe Newswire (Tue, 6-Jan 4:03 PM ET)
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Praxis Precision Medicines trades on the NASDAQ stock market under the symbol PRAX.
As of January 13, 2026, PRAX stock price climbed to $280.83 with 509,723 million shares trading.
PRAX has a beta of 2.00, meaning it tends to be more sensitive to market movements. PRAX has a correlation of 0.05 to the broad based SPY ETF.
PRAX has a market cap of $7.79 billion. This is considered a Mid Cap stock.
Last quarter Praxis Precision Medicines reported $0 in Revenue and -$3.36 earnings per share. This fell short of revenue expectation by $-59,440 and exceeded earnings estimates by $.11.
In the last 3 years, PRAX traded as high as $317.72 and as low as $11.85.
The top ETF exchange traded funds that PRAX belongs to (by Net Assets): IWM, VTI, XBI, IWN, IBB.
PRAX has outperformed the market in the last year with a return of +344.7%, while the SPY ETF gained +20.8%. In the last 3 month period, PRAX beat the market returning +427.3%, while SPY returned +6.5%. However, in the most recent 2 weeks PRAX has underperformed the stock market by returning -7.8%, while SPY returned +0.9%.
PRAX support price is $264.70 and resistance is $286.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRAX shares will trade within this expected range on the day.
